Alicia Irurzun-Lafitte

Private Equity Investor chez UCB Ventures (Private Equity)

Profil

Alicia Irurzun-Lafitte joined UCB Ventures in March 2019 as Partner.
Alicia joined from M Ventures, the corporate venture arm of Merck KGaA. Since 2014, she was instrumental in the closing of multiple new investments in Oncology, Immunology and Fertility areas in the US and Europe for the M Ventures Healthcare fund.
Alicia was also closely involved with the built-up of Merck spin-offs.
While at M Ventures, she served on the Board of Rewind Therapeutics as Director and Artios, iOnctura, Ribometrix, and TocopheRx as Observer.
Prior to ventures, Alicia held roles in global business development at Merck Serono in Geneva and EMD Serono in Boston.
During her time in business development she closed multiple early stage transactions and was involved in strategic corporate development initiatives.
Alicia holds a MSc from Leiden University in Biopharmaceutical Sciences.
She holds a Bachelor in Biomedical Sciences and completed her undergraduate studies between the University Claude Bernard Lyon 1 and Napier Edinburgh University.Alicia is based at the UCB Ventures’ Boston office and she lives in New York.

Postes actifs de Alicia Irurzun-Lafitte

Sociétés	Poste	Début
UCB Ventures (Private Equity)	Private Equity Investor	-

Anciens postes connus de Alicia Irurzun-Lafitte

Sociétés	Poste	Fin
Merck Ventures (USA)	Private Equity Investor	06/03/2019
TocopheRx, Inc.	Directeur/Membre du Conseil	-